+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Recombinant Human Lutropin alfa Market, 2018-2022

  • ID: 4720152
  • Report
  • December 2018
  • Region: China
  • 30 pages
  • China Research & Intelligence
1 of 4

FEATURED COMPANIES

  • Merck Serono
  • Merck Sharp & Dohme
  • MORE

According to the WHO’s estimate, infertility affects 15% to 20% of the global population. Survey data shows that in 2017, the incidence of infertility among married couples in China was 10%, more than double the 4.8% in 1984. As environmental pollution intensifies and lifestyle changes, the incidence of infertility is increasing and infertility is increasingly prevalent among Chinese young people. About 15% to 20% women of childbearing age in China are troubled by infertility. As the biggest cause of female infertility in China, follicular dysplasia syndrome resulting from endocrine dysfunction accounts for over 40% of infertility cases. In addition to reasonable adjustments to menstrual period and etiological treatment, for fertilization, it is necessary to adopt an ideal solution to promote the development and maturation of follicles in clinical treatment.

Since 2015 when the Chinese government relaxed its family planning policy, sex hormone drugs have been growing rapidly, and the infertility treatment and IVF, an assisted reproductive technology (ART), have attracted much attention. In China’s end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin Beta, Recombinant Human Chorionic Gonadotropin, and Human Lutropin alfa are taking the place of small-molecule chemicals.

Recombinant Human Lutropin alfa is a glycoprotein obtained by genetic engineering technique. It can combine with the luteinizing hormone/chorionic gonadotropin (LH/CG) receptor on the ovariole sheath (and granular layer) and the Leydig cell membrane. For women who lack luteinizing hormone and follicle-stimulating hormone (FSH) to ovulate, the use of LH can increase the level of estradiol secreted by the follicle and stimulate follicular development.

Merck Serono's Recombinant Human Lutropin alfa (trade name: Luveris) was approved to be sold in China in 2008. In 2017, the sales value exceeded CNY 30 million. By the end of 2018, China's Recombinant Human Lutropin alfa market will be monopolized by Merck Serono. According to this analysis, multinational companies such as Merck Serono and Merck Sharp & Dohme dominate China’s fertility drug market. Meanwhile, Chinese companies such as Livzon Pharmaceutical Group Inc., GeneScience Pharmaceuticals Co., Ltd., Zhejiang Xianju Pharmaceutical Co., Ltd., Hybio Pharmaceutical Co., Ltd., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. are also launching generic drugs. It is expected that the pattern of China's Recombinant Human Lutropin alfa market will change in the next few years.

In 2015, the Chinese government relaxed its “family planning policy” that had been implemented for over three decades, allowing each couple to have two children. In China, about 90 million women of childbearing age are eligible to have a second child. And an estimated 30% of them have the desire. Therefore, China's fertility drug market is promising.

Topics Covered:

  •  Situation of infertility in China
  •  Overview of China's fertility drug market
  •  Analysis on the fertility drug manufacturers in China
  •  Major factors influencing the development of fertility drugs in China
  •  Forecast on China's Recombinant Human Lutropin alfa market from 2018 to 2022
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Merck Serono
  • Merck Sharp & Dohme
  • MORE

1 Relevant Concepts of Recombinant Human Lutropin alfa
1.1 Indications for Recombinant Human Lutropin alfa
1.2 Development of Recombinant Human Lutropin alfa in China
1.3 Governmental Approval of Recombinant Human Lutropin alfa in China

2 Sales of Recombinant Human Lutropin alfa in China, 2013-2017
2.1 Sales Value of Recombinant Human Lutropin alfa
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Recombinant Human Lutropin alfa
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Recombinant Human Lutropin alfa by Dosage Form in China, 2013-2017

3 Analysis of Major Recombinant Human Lutropin alfa Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Recombinant Human Lutropin alfa Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Merck Serono
3.2.1 Enterprise Profile
3.2.2 Sales of Merck Serono's Recombinant Human Lutropin alfa in China

4 Prices of Recombinant Human Lutropin alfa in China, 2017-2018
4.1 Merck Serono (Luveris)
4.2 Prices of Other Fertility Drugs

5 Prospect of China's Recombinant Human Lutropin Alfa Market, 2018-2022
5.1 Major Factors Influencing Development of Recombinant Human Lutropin alfa in China
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Governmental Approval of Recombinant Human Lutropin alfa in China
Chart Sales Value of Recombinant Human Lutropin alfa in China, 2013-2017
Chart Sales Value of Recombinant Human Lutropin alfa in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Lutropin alfa in China, 2013-2017
Chart Sales Volume of Recombinant Human Lutropin alfa in Parts of China, 2013-2017
Chart Sales Value of Recombinant Human Lutropin alfa Injections in China, 2013-2017
Chart Sales Volume of Recombinant Human Lutropin alfa Injections in China, 2013-2017
Chart Sales Value of Merck Serono's Recombinant Human Lutropin alfa in China, 2013-2017
Chart Sales Volume of Merck Serono's Recombinant Human Lutropin alfa in China, 2013-2017
Chart Prices of Merck Serono's Recombinant Human Lutropin alfa in Parts of China, 2017-2018
Chart Forecast on Sales Value of Recombinant Human Lutropin alfa in China, 2018-2022

Note: Product cover images may vary from those shown
3 of 4
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • GeneScience Pharmaceuticals Co. Ltd.
  • Hybio Pharmaceutical Co. Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Merck Serono
  • Merck Sharp & Dohme
  • Zhejiang Xianju Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
4 of 4

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll